Detalles de la búsqueda
1.
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Breast Cancer Res Treat
; 168(1): 159-168, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177603
2.
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
Support Care Cancer
; 26(8): 2519-2549, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29796708
3.
Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
Support Care Cancer
; 24(5): 1941-1954, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26476625
4.
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Support Care Cancer
; 22(6): 1685-97, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24590374
5.
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Support Care Cancer
; 19(6): 807-13, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20461438
6.
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Support Care Cancer
; 19(9): 1297-302, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20623144
7.
A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients.
J Pain Symptom Manage
; 33(4): 365-71, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17397698
8.
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
J Clin Oncol
; 23(12): 2822-30, 2005 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15837996
9.
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
J Clin Oncol
; 21(22): 4112-9, 2003 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14559886
10.
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Eur J Cancer
; 41(9): 1278-85, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15939263
11.
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Breast Cancer Res Treat
; 108(1): 87-92, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17458693
12.
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
Cancer
; 104(7): 1548-55, 2005 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16104039
Resultados
1 -
12
de 12
1
Próxima >
>>